Endothelin and isoproterenol counter-regulate cAMP and mitogen-activated protein kinases.
Mitogen-activated protein kinases (MAPK) and cAMP are important components of the intracellular signaling pathways. We studied the effects of endothelin-1 (ET-1) and isoproterenol (ISO) on the intracellular cAMP level in human pericardial smooth-muscle cells and investigated how these two ligands regulate the activity of MAPK (p42/p44 MAPK). ET-1 or ET-3 alone did not exhibit any effect on the cAMP level in these cells. In contrast, ISO at 10 microM caused a 12-fold increase in the accumulation of cAMP (370 +/- 70 pmol/ml vs. 31 +/- 5 pmol/ml). Addition of ET-1 attenuated ISO-stimulated cAMP accumulation by 50% in a dose-dependent manner, with an IC50 of 0.12 nM. ET-3 was 100-fold less potent (IC50 = 15 nM). The attenuating effect of ET-1 was completely blocked by 1 microM FR139317, suggesting that the effect is primarily mediated by the ETA receptor. In serum-deprived cells, the basal MAPK activity was low (0.07 +/- 0.01 nmoles Pi/mg/min). Addition of 10 nM ET-1 stimulated MAPK 15-fold within 5 min at 37 degrees C (1.08 +/- 0.02 nmoles Pi/mg/min). ISO alone (10 microM) had no significant effect on MAPK. However, ISO markedly attenuated ET-1-stimulated MAPK activity; a approximately 50% decrease in MAPK activity was observed in the presence of 10 microM ISO. Similar results were obtained when forskolin was tested. The effects of ISO and forskolin on attenuating ET-1-stimulated MAPK activity could be reversed by treating cells with H89, an inhibitor of protein kinase A. These results show that ET-1 partially attenuated the accumulation of cAMP induced by ISO, and that ISO attenuated the MAPK activity induced by ET-1, possibly via activation of protein kinase A. This study suggests that counter-regulation among various ligands and cross-talk among different signaling pathways may be required to modulate biologic functions in a living cell.
Wu-Wong
J R
JR
Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, IL 60064-3500, USA.
Opgenorth
T J
TJ
D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D015153:Blotting, Western; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000096:biosynthesis*; D002478:Cells, Cultured; D002852:Chromatography, Ion Exchange; D000242:Cyclic AMP / Q000096:biosynthesis*; D017868:Cyclic AMP-Dependent Protein Kinases / Q000378:metabolism; D004347:Drug Interactions; D004591:Electrophoresis, Polyacrylamide Gel; D019332:Endothelin-1 / Q000494:pharmacology*; D004789:Enzyme Activation / Q000187:drug effects; D006801:Humans; D007545:Isoproterenol / Q000494:pharmacology*
D000318:Adrenergic beta-Agonists; D019332:Endothelin-1; D000242:Cyclic AMP; D017868:Cyclic AMP-Dependent Protein Kinases; D017871:Calcium-Calmodulin-Dependent Protein Kinases; D007545:Isoproterenol